A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma

NCT06438614 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Refractory Neuroblastoma
Soft Tissue Cancer

Interventions

DRUG: HITS
DRUG: Naxitamab + GM-CSF cycles
DRUG: NICE

Sponsor

Fundació Sant Joan de Déu